Skip to main content
Journal cover image

Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05).

Publication ,  Journal Article
Lawton, CA; DeSilvio, M; Lee, WR; Gomella, L; Grignon, D; Gillin, M; Morton, G; Pisansky, T; Sandler, H
Published in: Int J Radiat Oncol Biol Phys
January 1, 2007

PURPOSE: To evaluate the effectiveness of transrectal ultrasound-guided permanent radioactive (125)I implantation of the prostate for organ-confined adenocarcinoma of the prostate compared with historical data of prostatectomy and external beam radiotherapy within a cooperative group setting. METHODS AND MATERIALS: Patients accrued to this study had histologically confirmed, locally confined, adenocarcinoma of the prostate with clinical Stage T1b, T1c, or T2a, no nodal or metastatic disease, prostate-specific antigen level of < or =10 ng/mL, and Gleason score of < or =6. All patients underwent transrectal ultrasound-guided radioactive (125)I permanent seed implantation into the prostate. The prescribed dose was 145 Gy to the prostate planning target volume. RESULTS: A total of 27 institutions accrued a total of 101 patients to this protocol, with no institution accruing >8 patients. Six patients were ineligible, leaving 95 properly entered as eligible in the study. The median follow-up was 5.3 years (range, 0.4-6.5 years). At 5 years, 5 patients had local failure, 1 had evidence of distant failure, and 6 (6%) had biochemical failure. The overall survival rate at 5 years was 96.7%. At last follow-up, no patient had died of prostate cancer or related toxicities. Eight patients had a maximal acute toxicity level of 3, and no patient had Grade 4 or 5 acute toxicity. During follow-up, 2 patients had maximal Grade 3 toxicity, both related to bladder issues, and no patient experienced Grade 4 or 5 toxicity. CONCLUSION: The results of this clinical protocol (a multi-institutional trial of brachytherapy for localized adenocarcinoma of the prostate) have demonstrated that this type of trial can be successfully completed through the Radiation Therapy Oncology Group. Biochemical disease-free survival was comparable with other brachytherapy published series and with the results after surgery and external beam radiotherapy.

Duke Scholars

Published In

Int J Radiat Oncol Biol Phys

DOI

ISSN

0360-3016

Publication Date

January 1, 2007

Volume

67

Issue

1

Start / End Page

39 / 47

Location

United States

Related Subject Headings

  • Ultrasonography, Interventional
  • Radiotherapy Dosage
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Middle Aged
  • Male
  • Iodine Radioisotopes
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lawton, C. A., DeSilvio, M., Lee, W. R., Gomella, L., Grignon, D., Gillin, M., … Sandler, H. (2007). Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). Int J Radiat Oncol Biol Phys, 67(1), 39–47. https://doi.org/10.1016/j.ijrobp.2006.08.016
Lawton, Colleen A., Michelle DeSilvio, W Robert Lee, Leonard Gomella, David Grignon, Michael Gillin, Gerard Morton, Thomas Pisansky, and Howard Sandler. “Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05).Int J Radiat Oncol Biol Phys 67, no. 1 (January 1, 2007): 39–47. https://doi.org/10.1016/j.ijrobp.2006.08.016.
Lawton CA, DeSilvio M, Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky T, Sandler H. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):39–47.
Journal cover image

Published In

Int J Radiat Oncol Biol Phys

DOI

ISSN

0360-3016

Publication Date

January 1, 2007

Volume

67

Issue

1

Start / End Page

39 / 47

Location

United States

Related Subject Headings

  • Ultrasonography, Interventional
  • Radiotherapy Dosage
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Middle Aged
  • Male
  • Iodine Radioisotopes